Results 161 to 170 of about 61,634 (258)
The oscillatory response of the electroretinogram and neuronal adaptation
Acta Ophthalmologica, EarlyView.Abstract After more than 50 years, there still remains a challenge and an interest to know more as well as extend and deepen our understanding of the small rapid wavelets, the oscillatory potentials (OPs), of the electroretinogram (ERG) and the neuronal adaptation of the retina.
Lillemor Wachtmeister, Anders Eklund
wiley +1 more source
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease. [PDF]
Eur J NeurolStaubo SC +12 more
europepmc +1 more source
Acta Ophthalmologica, EarlyView.Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen +3 more
wiley +1 more source
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson's Disease. [PDF]
CNS Neurol Disord Drug TargetsBezard E +5 more
europepmc +1 more source
Limited Evidence of Noradrenaline Use and Effectiveness in Preterm Neonates: A Systematic Review
Acta Paediatrica, EarlyView.ABSTRACT Aim The study aimed to analyse the effects and associated outcomes of noradrenaline in treating hypotension in preterm neonates. Methods We searched PubMed, Web of Science, and Scopus to August 2025 for randomised and observational studies on noradrenaline use in preterm neonates.
A. Vänskä, U. Sankilampi, I. Kuitunen
wiley +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, EarlyView.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, EarlyView.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source